Symptoms, Ca125 And He4 For The Preoperative Prediction Of Ovarian Malignancy In Brazilian Women With Ovarian Masses. by Pitta, Denise da Rocha et al.
Pitta et al. BMC Cancer 2013, 13:423
http://www.biomedcentral.com/1471-2407/13/423RESEARCH ARTICLE Open AccessSymptoms, CA125 and HE4 for the preoperative
prediction of ovarian malignancy in Brazilian
women with ovarian masses
Denise da Rocha Pitta1, Luis Otávio Sarian1, Amilcar Barreta2, Elisabete Aparecida Campos1,
Liliana Lucci de Angelo Andrade3, Ana Maria Dias Fachini2, Leonardo Martins Campbell2 and Sophie Derchain1*Abstract
Background: This manuscript evaluates whether specific symptoms, a symptom index (SI), CA125 and HE4 can
help identify women with malignant tumors in the group of women with adnexal masses previously diagnosed
with ultrasound.
Methods: This was a cross-sectional study with data collection between January 2010 and January 2012. We invited
176 women with adnexal masses of suspected ovarian origin, attending the hospital of the Department of
Obstetrics and Gynecology of the Unicamp School of Medicine. A control group of 150 healthy women was also
enrolled. Symptoms were assessed with a questionnaire tested previously. Women with adnexal masses were
interviewed before surgery to avoid recall bias. The Ward Agglomerative Method was used to define symptom
clusters. Serum measurements of CA125 and HE4 were made. The Risk of Ovarian Malignancy Algorithm (ROMA)
was calculated using standard formulae.
Results: Sixty women had ovarian cancer and 116 benign ovarian tumors. Six symptom clusters were formed and
three specific symptoms (back pain, leg swelling and able to feel abdominal mass) did not agglomerate. A
symptom index (SI) using clusters abdomen, pain and eating was formed. The sensitivity of the SI in discriminating
women with malignant from those with benign ovarian tumors was 78.3%, with a specificity of 60.3%. Positive SI
was more frequent in women with malignant than in women with benign tumors (OR 5.5; 95% CI 2.7 to 11.3).
Elevated CA125 (OR 11.8; 95% CI 5.6 to 24.6) or HE4 (OR 7.6; 95% CI 3.7 to 15.6) or positive ROMA (OR 9.5; 95%
CI 4.4 to 20.3) were found in women with malignant tumors compared with women with benign tumors. The AUC-
ROC for CA125 was not different from that for HE4 or ROMA. The best specificity and negative predictive values
were obtained using CA125 in women with negative SI.
Conclusion: Women diagnosed with an adnexal mass could benefit from a short enquiry about presence,
frequency and onset of six symptoms, and CA125 measurements. Primary care physicians can be thereby assisted in
deciding as to whether or not reference the woman to often busy, congested specialized oncology centers.
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Each year, nearly 255.000 new cases of ovarian cancer
are diagnosed. Ovarian cancers are the 7th most com-
mon type of cancer in women, leading the mortality rate
among gynecological cancers by causing 140.000 deaths
per year [1]. The incidence of ovarian cancer is higher in
industrialized countries, although developing countries,
due to larger populations, hold the majority of cases
(96.700 vs 107.500). In Latin America, the 8/100.000 in-
cidence is close to that of developed countries, which is
10/100.000 women. It was expected that 6.190 ovarian
cancer cases would have been diagnosed in Brazil in 2012,
with an estimated risk of 6:100.000 women. Not consider-
ing non-melanoma skin cancer, ovarian cancer is the sev-
enth most frequent cancer in Brazilian women [2].
In general, ovarian malignancies are diagnosed at an
advanced stage, when symptoms are clearly present, or
incidentally, at an earlier stage, when an ultrasound is
made. It has long been demonstrated that long term sur-
vival of ovarian cancer patients is better when these
women are treated in specialized training centers, by gy-
necologists with expertise in gynecologic oncology [3].
In Brazil, a substantial share of the patients is operated
by ‘semi-specialized’ gynecologists without formal train-
ing but with experience in oncology, generally in high-
volume centers specialized in cancer. This professional
is likely to be able to perform staging surgery for tumors
apparently confined to the ovaries, and debulking sur-
gery for advanced stage disease [3].
The preoperative assessment of an adnexal mass is dif-
ficult, leading to a disproportionate number of women
with benign ovarian tumors being referred to specialized
centers and vice-versa, i.e., women with ovarian cancer
being inappropriately operated in non-specialized cen-
ters. In a systematic review, Geomini et al. [4] demon-
strated that the Risk of Malignancy Indexes (RMI) I and
II, which use the product of the serum CA125 level, an
ultrasound scan result, and the menopausal state, were
the best predictors of malignancy in the preoperative as-
sessment of adnexal masses. Since 1999, the authors of
the International Ovarian Tumor Analysis (IOTA) study
have been analyzing a large cohort of patients with per-
sistent adnexal masses, in different clinical centers using
a standardized ultrasound protocol [5]. Their results
consistently showed that using algorithms or even the
application of simple and straightforward ultrasound
classifications are the most accurate ways of identifying
patients with malignant ovarian tumors [5,6]. These al-
gorithms and simple rules have been extensively vali-
dated [5,6]. In a recent study we tested the IOTA simple
ultrasound rules [7] to identify malignant tumors in
women with adnexal masses, resulting in a net sensitiv-
ity of 90%, specificity of 87%, positive predictive value
(PPV) of 69% and negative predictive value (NPV) of97% [7]. However, it must be emphasized that the high
performance of IOTA-based ultrasound was obtained in
the hands of examiners with high level of ultrasound ex-
perience. These experienced examiners are more likely
to be found in specialized centers.
Recently, many studies examined whether symptoms
could help in the selection of women at high risk of har-
boring a malignant ovarian tumor. More than 90% of
women with ovarian cancer report at least one symptom
and these symptoms are most often the reason for the
visit leading to the diagnosis. However, it remains un-
known whether the evaluation of these symptoms is able
to discriminate women with malignant ovarian tumors
from women with benign adnexal masses [8]. It appears
that women with ovarian cancer at any stage are more
likely than their counterparts with ovarian benign
masses to experience very frequent, sudden onset and
persistent symptoms [8-11].
In parallel, CA125 serum measurements may also con-
tribute to the identification of ovarian malignancies, al-
though recent studies suggest that this contribution may
be marginal [12,13]. For this reason, novel biomarkers
that may help the differentiation of women with malig-
nant tumors are currently under intensive scrutiny [14].
Moore and colleagues [15] have explored a large number
of new biomarkers and recently the Food and Drug
Administration approved HE4 and the Risk of Malig-
nancy Algorithm (ROMA) for the diagnosis of ovarian
cancer in woman with a clinically detectable ovarian
mass. However, the diagnostic accuracy of HE4 and
ROMA is still controversial. In a recent meta-analysis, Li
et al. [14] concluded that although ROMA can help dis-
tinguish epithelial ovarian cancer from benign pelvic
masses, HE4 is not better than CA125 for ovarian cancer
prediction.
In the present study, we investigated whether the pre-
operative evaluation of specific symptoms and tumor
markers in Brazilian women with suspected adnexal
masses previously diagnosed with ultrasound may help
in the identification of the women who harbor a malig-
nant ovarian tumor. We also evaluated the presence of
these symptoms in a group of controls to assess the like-
lihood of healthy women to experience symptoms asso-
ciated with adnexal tumors.
Methods
Patient selection
This was a cross-sectional study with prospective data
collection. The study was approved by the institutional
review board of the Unicamp School of Medicine (proto-
col #1092/2009). An informed consent was obtained
from all participants. Women with adnexal masses of
suspected ovarian origin attending the hospital of the
Department of Obstetrics and Gynecology of the
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control group of healthy women attending menopause
and family planning clinics at the same hospital was se-
lected. As soon as surgery was indicated, women who
had adnexal masses received an explanation about the
study methods and purpose. Symptoms were assessed
with a questionnaire previously tested and published by
Goff et al. [9]. The questionnaire was applied to all
women, in-person, by a trained professional (DRP).
Women with adnexal masses were interviewed before
surgery to avoid recall bias, since the main purpose of
the study was to investigate whether symptoms could
help to preoperatively discriminate women with malig-
nant ovarian tumors. We also collected data on age and
body mass index (BMI). Peripheral blood was collected
for serum measurements of CA125 and HE4. The mean
time elapsed from interview, blood collection to surgery
ranged 24 h or less for emergency procedures to a max-
imum of 120 days. Exclusion criteria comprised women
who had already been operated for the adnexal mass and
ongoing pregnancy. The final sample of this study
consisted of 176 women with adnexal masses of ovarian
origin and 150 healthy women. Patient accrual ranged
January 2010 – January 2012, and collection of data re-
garding the marker status and pathological diagnoses
lasted through May 2012.
Symptoms
As previously stated, women with adnexal masses were
surveyed prior to surgery, before they knew their histo-
logical diagnosis. The survey evaluated the presence, fre-
quency and duration of pelvic pain, abdominal pain,
back pain, indigestion, being unable to eat normally,
feeling full quickly, having nausea or vomiting, weight
loss, abdominal bloating, increased abdomen size, being
able to feel abdominal mass, urinary urgency, frequent
urination, constipation, diarrhea, menstrual irregularity,
bleeding after menopause, pain during intercourse,
bleeding with intercourse, fatigue, leg swelling, and diffi-
culty breathing. The survey was originally designed in
English and was submitted to a Portuguese translation,
which included two forward translations, one reconciled
version and a back translation of the reconciled version.
Initially, the patient was questioned about the presence
or absence of a symptom. If present, the severity of each
symptom along with its frequency and duration were
evaluated. The frequency was reported with respect to
the number of days per month, classified as: <1, 1–2, 3–6,
7–12, 13–19 or >20 days/month. The duration was
reported with respect to how long the symptom persisted.
Next, the patient was asked during how many of the
previous 12 months did the symptom occur, which
was further categorized in <1, 1–2, 3–4, 5–6, 7–9, 10–
12, >12 months. This symptom categorization emphasizesonset and frequency, since previous studies demonstrated
that these two features are strongly related to malignancy
[9,11]. We considered a symptom positive if it occurred
more than 12 times per month, beginning in the last year,
regardless of this severity [9,16].
Serum samples and marker assays
Blood samples were collected from all patients and
stored in Serum Separator Tubes (SST). They were
allowed to clot for at least 30 minutes before centrifuga-
tion. The blood samples were centrifuged 1300 g for
10 min, and serum was aliquoted and stored at −80°C
until analysis. Automated analysis of CA125 was
performed by solid phase chemiluminescence using the
OM-MA test (Siemens Medical Solutions Diagnostics,
Tarrytown, USA) according to the manufacturer’s in-
structions and using their reagents and equipment.
Values were expressed in units per milliliter (U/mL). We
used the Immunochemiluminometric assay ([ICMA],
Immulite® 2000 OM-MA, Siemens Medical Solutions
Diagnostics) for CA125 measurements. The ROMA™
preconizes the use of the ARCHITECT CA125 II™ assay,
which is a Chemiluminescent Microparticle Immuno-
assay (CMIA), essentially the same technology as ICMA.
According to Li et al. [14] CA125 tests with EIA
(enzyme immunoassay) and RIA (radioimmunoassay)
are considered “High Concern Regarding Applicability”.
CMIA and ICMA are thus equivalent technologies that
can be used interchangeably. The level of serum HE4
was determined using the HE4 enzyme immunometric
assay Kits (EIA) (Fujirebio Diagnostics, Göteborg,
Sweden) based on the direct sandwich technique, solid-
phase immunoassay according to the manufacturer’s in-
structions and using their reagents and equipment.
Values were expressed in picomoles per liter (pMol/L).
Calculation of the Risk of Ovarian Malignancy Algorithm
(ROMA)
The Risk of Ovarian Malignancy Algorithm (ROMA™)
uses the ABBOT ARCHITECT™ platform results for
HE4 and CA125 to generate a predictive index (PI) for
epithelial ovarian cancer, calculated by the formulae pro-
posed by Moore et al. [15] for pre-menopausal and post-
menopausal women. The manufacturer recommends the
ROMA™ index to be used to stratify women into high-
risk or low-risk groups of having epithelial ovarian
cancer (EOC). We decided to use ROMA for the dis-
crimination of women with ovarian malignancies, not
only EOC. The ROMA™ risk estimation is based on the
ABBOT ARCHITECT™ platform; however, since we used
the OM-MA test for CA125 (Siemens Medical Solutions
Diagnostics, Tarrytown, USA) and the HE4 EIA Kit
(Fujirebio Diagnostics), differences in assay methods and
reagent specificity could lead to different performances.
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performance obtained with our sample (see statistics).
Surgery and pathological assessment of tumor specimens
Surgeries for diagnosis and/or treatment were performed
at the hospital of the Department of Obstetrics and
Gynecology of Unicamp School of Medicine and the
techniques and surgical procedures were chosen and
performed according to medical indication. All women
with ovarian cancer were fully staged. The gold standard
was the histopathologic diagnosis of surgical specimens,
rendered by pathologists of the Department of Patho-
logic Anatomy of the Unicamp School of Medicine, fol-
lowing the guidelines of the World Health Organization
International Classification of Ovarian Tumors [17]. For
statistical purposes, the epithelial borderline tumors
were classified as malignant (i.e. 10 out of 47 epithelial
malignant tumors were rendered as borderline).
Statistical analysis
Data were entered into a Microsoft Excel (Microsoft
Corp., Redmond, WA, USA) spreadsheet and analyzed
with the R Environment for Statistical Computing Soft-
ware® [18]. All statistical calculations were performed
using 95% confidence intervals (CIs) and P <0.05 was
considered significant. Women were classified into be-
nign and malignant groups according to tumor histo-
logic diagnoses. The sample size was calculated on the
basis of the difference in symptom prevalence derived
from previous studies [19,20], with 5% significance
levels, 80% statistical power and 12% error limits for the
sensitivity. Using these parameters, the minimal number
of women with malignant tumors would be 54, and
based on the prevalence of malignancy, 112 women with
benign tumors would be needed for discrimination.
Data analysis plan
We first compared the main clinical features of the
women in the three study groups using chi-squares, and
the Kruskal-Wallis test for continuous numerical vari-
ables such as age and BMI. Pairwise comparisons were
done: women with malignant tumors vs. those with be-
nign tumors; malignant vs. controls, and benign vs. con-
trols. Next, using the pairwise groupings listed before,
we compared the proportions of women presenting with
each of the 22 specific symptoms. A dichotomous classi-
fication for each symptom was used: positive if the
symptoms had occurred more than 12 times, beginning
in the last year, regardless of its severity; negative if
otherwise. The proportions were pairwise compared
using chi-squares or the Fisher exact test where appro-
priate. Because the prevalence of symptoms was very
low in control women, this group was excluded from the
subsequent analyses (Table 1).Determination of symptom clusters
The Ward’s Hierarchical Clustering Method [21] was
used to evaluate whether the specific symptoms could
be clustered in women with malignant or benign ovarian
tumors. The following specific symptoms were not in-
cluded in the Ward’s model: menstrual irregularity,
bleeding after menopause, pain during intercourse, and
bleeding with intercourse, because these symptoms de-
pend on menopausal status and sexual activity; constipa-
tion and diarrhea, because these symptoms appeared
very rarely; and weight loss, because frequency could not
be ascertained for that symptom. Thus, sixteen specific
symptoms were entered into the Ward model. This
method allows for the formation of statistically signifi-
cant agglomerates of symptoms, which were depicted in
the Euclidian plane (Figure 1): related symptoms appear
close to each other; the closer they are, the more related
to each other. We compared the prevalence of the symp-
tom clusters and the remaining isolated symptoms in
women with either malignant or benign tumors using
crude (unadjusted) odds ratios and chi-squares/Fisher
Exact test. We also calculated the performance indica-
tors (sensitivity, specificity, with 95% confidence inter-
vals, positive and negative predictive values – PPV and
NPV) for each symptom cluster and isolated symptom
in discriminating malignant from benign tumors. Goff
et al. (2007) [9] proposed a “symptom index” (SI) that
was most predictive of a women having ovarian cancer;
the SI is considered positive if the women has at least
one of the following symptom groupings: abdominal or
pelvic pain, feeling full quickly or unable to eat normally,
or increased abdomen size. Coincidentally, in our study,
these symptoms formed identical clusters and were the
most sensitive and prevalent. We thus decided to repli-
cate Goff ’s SI in our study.
Determination of CA125, HE4 and the ROMA predictive
index cutoff points
We used standard receiver operator characteristics
(ROC) analysis to determine the best CA125, HE4 and
ROMA index cutoff points in discriminating benign
from malignant ovarian tumors. In premenopausal
women, the optimal cutoff points for CA125, HE4 and
ROMA predictive index were, respectively, 69.8 U/L,
41.6 pmol/L and 5.01%. In postmenopausal women these
cutoff points were, respectively, 21.7 U/L, 96.6 pmol/L
and 18.2%. ROC AUC comparisons were performed with
the DeLong method [22].
Accuracy of symptom clusters, symptom index and tumor
markers
We performed pairwise comparisons of prevalence of
the symptom clusters, symptom index, and the positivity
rate of CA125, HE4 and ROMA index according to
Table 1 Specific symptoms in women with malignant or benign ovarian tumors and controls (healthy women)
Malignant
tumors
Benign
tumors
Controls p-value p-value p-value
(n = 60) (n = 116) (150) (Malignant vs. benign) (Malignant vs. controls) (Benign vs. controls)
Symptom N (%) n (%) n (%)
Pelvic pain 30 (50.0) 23 (19.7) 2 (1.3) <0.01 <0.01 <0.01
Abdominal pain 23 (38.3) 10 (8.5) 0 - <0.01 <0.01 <0.01
Back pain 17 (28.3) 10 (8.6) 0 - <0.01 <0.01 <0.01
Unable to eat normally 22 (36.7) 8 (6.8) 1 (0.7) <0.01 <0.01 0.01
Feeling full quickly 22 (36.1) 11 (9.4) 1 (0.7) <0.01 <0.01 <0.01
Indigestion 15 (24.6) 7 (6.0) 1 (0.7) <0.01 <0.01 0.02
Nausea or vomiting 11 (18.0) 4 (3.4) 1 (0.7) <0.01 <0.01 0.17
Weight loss 19 (31.7) 25 (21.6) 11 (7.3) 0.19 <0.01 <0.01
Abdominal bloating 36 (60.0) 32 (27.4) 0 - <0.01 <0.01 <0.01
Increased abdomen size 38 (63.3) 31 (26.7) 1 (0.7) <0.01 <0.01 <0.01
Able to feel abdominal mass 14 (23.3) 11 (9.4) 0 - 0.02 <0.01 <0.01
Urinary urgency 8 (13.3) 8 (6.8) 2 (1.3) 0.25 <0.01 0.02
Frequent urination 12 (20.0) 16 (13.7) 2 (1.3) 0.38 <0.01 <0.01
Constipation 2 (3.3) 2 (1.7) 0 - 0.60 0.08 0.18
Diarrhea 3 (5.1) 1 (0.9) 0 - 0.11 0.02 0.43
Menstrual irregularities* 1 (1.6) 1 (0.9) 1 (0.7) 1.0 0.49 1.0
Bleeding after menopause** 6 (10.0) 1 (0.9) 0 - <0.01 <0.01 0.43
Pain during intercourse*** 0 - 0 - 1 (0.7) NC 1.0 1.0
Bleeding with intercourse 0 - 0 - 0 - NC NC NC
Fatigue 20 (33.3) 16 (13.7) 3 (2.0) <0.01 <0.01 <0.01
Leg swelling 6 (10.0) 11 (9.4) 1 (0.7) 1.0 <0.01 <0.01
Difficulty breathing 9 (15.0) 5 (4.3) 2 (1.3) 0.02 <0.01 0.24
*only for premenopausal women; **only for postmenopausal women; ***only for sexually active women; NC non-computable.
P-value: bivariate pairwise comparisons using chi-squares or the Fisher’s exact test where appropriate.
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odds ratios with 95% CI. Next, we calculated the per-
formance indicators (sensitivity, specificity, with 95%
confidence intervals, positive and negative predictive
values) for the symptom clusters and tumor markers
using standard formulae.
Results
Table 2 shows the comparison of key clinical features of
women with malignant or benign ovarian tumors and
controls. The mean age was significantly higher in
women with malignant tumors. BMI was balanced be-
tween the study groups. Epithelial benign and malignant
tumors prevailed over the other histological types, but
germ line (mature teratomas) and stromal tumors (fibro-
mas) were also common in women with benign tumors.
More than 50% of the women with malignant tumors
had stage I disease.
Women with malignant tumors showed a higher fre-
quency of symptoms such as pelvic pain, abdominal
pain, back pain, being unable to eat normally, feeling fullquickly, indigestion, abdominal bloating, increased ab-
dominal size, being able to feel abdominal mass and fa-
tigue when compared with women with benign ovarian
tumors. The prevalence of symptoms in control women
was very low, with the exception of weight loss. This fact
led us to exclude controls from the subsequent analyses
(Table 1).
Figure 1 shows the Euclidian representation of the
Ward Agglomerative Method used to define the symp-
tom clusters. This method was able to define 6 different
clusters of symptoms. These clusters were named as fol-
lows: abdomen (agglomeration of the following specific
symptoms: abdominal bloating and/or increased abdom-
inal size); pain (pelvic and/or abdominal pain); digestion
(indigestion and/or nauseas/vomiting); eating (unable to
eat normally and/or feeling full quickly); miscellaneous
(fatigue and/or difficulty breathing) and bladder (urinary
urgency and/or frequent urination). Three specific symp-
toms (back pain, leg swelling and able to feel abdominal
mass) did not agglomerate and remained as isolated
symptoms.
Figure 1 Ward agglomerative method for hierarchical clustering. The following clusters of symptoms and isolated symptoms were defined
by the Ward agglomerative method: abdomen (abdominal bloating and/or increased abdominal size); back pain; pain (pelvic and/or abdominal
pain); leg swelling; eating (unable to eat normally and/or feeling full quickly); able to feel abdominal mass; miscellaneous (fatigue and/or difficulty
breathing); digestion (indigestion and/or nauseas/vomiting); bladder (urinary urgency and/or frequent urination).
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and isolated symptoms in women with benign or malig-
nant ovarian tumors. Clusters and isolated symptoms
were sorted according to decreasing prevalence in the
studied population. With the exception of the cluster
bladder and the isolated symptoms leg swelling, all
symptoms were significantly more prevalent in women
with malignant tumors.
Table 4 compares the performance of the symptom clus-
ters, isolated symptoms, and SI in discriminating women
with malignant ovarian tumors from the others. Clusters
and symptoms were ordered from the most to the least
sensitive. Clusters abdomen, pain and eating were the
most sensitive and those with the best PPV, and were
therefore chosen to be used in the symptom index (SI)
calculation. The sensitivity of the SI in discriminating
women with malignant from those with benign ovarian
tumors was 78.3%, with a specificity of 60.3%.
In Table 5, we compared the prevalence of the three
most sensitive symptom clusters, the SI, and thepositivity rate of CA125, HE4, and ROMA predictive
index across histological and stage strata. The percent-
age of women with ovarian malignancy who experienced
at least one cluster of symptoms ranged 37% to 72%,
and this prevalence was not significantly associated with
disease stage. The proportion of women with positive SI
did not vary significantly across disease stage strata, with
figures around 78%. The proportion of women with posi-
tive SI was also significantly lower in women with benign
tumors compared to women with stage I disease. Women
with malignant tumors had significantly more elevated
levels of the tumor markers compared to women with be-
nign tumors. However, only 34% of the women with stage
I disease had positive ROMA predictive index (PI),
contrasted to 84% in women with advanced stage disease.
It is worth noting, 40% of the women with benign tumors
had positive SI, but only 12% of these women had positive
ROMA PI.
In Table 6 we evaluated the performance of the tumor
markers in differentiating women with malignant tumors
Table 2 Key clinical features of women with ovarian malignant tumors, ovarian benign tumors and healthy women
(controls)
Characteristics Malignant Benign Controls p-value p-value p-value
(n = 60) (n = 116) (n = 150) (Malignant vs. benign) (Malignant vs. controls) (Benign vs. controls)
Age
Years, mean (SD)* 50.8 (20.5) 47.9 (16.6) 44.4 (12.6) 0.45 0.02 0.18
Menopausal statusŦ
Premenopausal 23 (38.3) 68 (57.8) 79 (52.6)
Postmenopausal 38 (61.7) 49 (42.2) 71 (48.4) <0.01 0.05 0.37
Body mass index (BMI) – kg/m2
Mean (+/− SD)* 28.3 (+/−6.3) 28.0 (+/−5.5) 27.2 (+/−5.0) 0.42 0.37 0.40
Histology
Epithelial 47 (78.3) 40 (34.5) - - - -
Invasive 37 (78.7)
Borderline 10 (21.3)
Germ line 6 (10.0) 28 (24.1) - - - -
Sex cord and Stromal 7 (12.7) 20 (17.3) - - - -
Non-neoplasic - 28 (24.1) - - - -
Stage
I 32 (53.3)
II 5 (8.3)
III 22 (36.7)
IV 1 (1.7)
p values calculated with either chi-squaresŦ or the Kruskal-Wallis test*.
*2 ovarian carcinomas had endometrial carcinoma associated; for these cases ovarian carcinoma was considered the primary tumor.
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benign tumors in subsets of women with different symp-
tom patterns. The AUC-ROC for CA125 was not signifi-
cantly different from that for HE4 or ROMA in
discriminating malignant (all stages) or only stage I tu-
mors from benign tumors. The tumor markers yielded
their best NPV and specificity in women with negative
SI. Using the tumor markers in addition to the SI (the
stand-alone performance of the SI is shown in Table 4)Table 3 Prevalence of symptoms clusters/isolated symptoms
Symptoms Malignant positive N (%) Be
Cluster abdomen 41(68.3)
Cluster pain 33 (55.0)
Cluster eating 27 (45.0)
Cluster miscellaneous 21 (35.0)
Cluster digestion 18 (30.0)
Back Pain 17 (28.3)
Able to feel abdominal mass 14 (23.3)
Cluster bladder 14 (23.3)
Leg swelling 6 (10.0)
Clusters of symptoms and isolated symptoms were defined by the Ward agglomera
pain (pelvic and/or abdominal pain); eating (unable to eat normally and/or feeling f
(indigestion and/or nauseas/vomiting); back pain; able to feel abdominal mass; bladincreases the specificity and the PPV of the differenti-
ation strategy for malignant (all stages) from benign
ovarian masses, but this does not hold true if we want to
differentiate stage I disease from benign tumors.
Discussion
In this sample of Brazilian women who underwent sur-
gery due to a suspected adnexal mass, the evaluation of
specific symptoms proved to be a powerful tool for theaccording to tumor malignancy
nign positive N (%) Crude odds ratio (95% CI) p
36 (31.0) 4.7 (2.4 to 9.3) <0.01
26 (22.4) 4.2 (2.1 to 8.2) <0.01
14 (12.0) 5.9 (2.8 to 12.6) <0.01
18 (15.4) 2.9 (1.4 to 6.0) 0.01
10 (8.5) 4.5 (1.9 to 10.5) 0.01
10 (8.6) 4.1 (1.8 to 9.8) <0.01
11 (9.4) 2.9 (1.2 to 6.8) 0.02
20 (17.1) 1.4 (0.7 to 3.1) 0.42
11 (9.4) 1.1 (0.4 to 3.0) 1.0
tive method: abdomen (abdominal bloating and/or increased abdominal size);
ull quickly); miscellaneous (fatigue and/or difficulty breathing); digestion
der (urinary urgency and/or frequent urination), leg swelling.
Table 4 Performance of cluster of symptoms and the symptom index for the differentiation of women with malignant
ovarian tumors from women with benign tumors
Symptoms Sensitivity (%) (95% CI) Specificity (%) (95%) PPV (%) NPV(%)
Cluster abdomen 68.3 (59.9 to 63.1) 69.0 (58.6 to 79.3) 80.8 53.2
Cluster pain 55.0 (45.0 to 64.0) 77.8 (67.2 to 88.4) 77.1 55.0
Cluster eating 45.0 (36.0 to 54.0) 88.0 (78.1 to 98.0) 75.7 65.8
Cluster miscellaneous 35.0 (26.3 to 43.6) 84.6 (73.3 to 96.0) 71.7 53.8
Cluster digestion 29.5 (21.2 to 37.8) 91.4 (81.1 to 100.0) 71.3 64.3
Back Pain 28.3 (20.1 to 36.5) 91.4 (80.8 to 100) 71.1 63.0
Able to feel abdominal mass 23.3 (15.7 to 31.0) 90.6 (79.1 to 100) 69.7 56.0
Cluster bladder 23.3 (15.7 to 31.0) 82.9 (70.2 to 95.6) 67.8 41.2
Leg swelling 10.0 (4.6 to 15.4) 90.6 (76.7 to 100) 66.2 35.3
Symptom index (SI) 78.3 (70.8 to 85.8) 60.3 (5.4 to 70.3) 50.5 84.3
Clusters of symptoms and isolated symptoms were defined by the Ward agglomerative method: abdomen (abdominal bloating and/or increased abdominal size);
pain (pelvic and/or abdominal pain); eating (unable to eat normally and/or feeling full quickly); miscellaneous (fatigue and/or difficulty breathing); digestion
(indigestion and/or nauseas/vomiting); back pain; able to feel abdominal mass; bladder (urinary urgency and/or frequent urination), leg swelling. Symptom index
(SI) = presence of at least one of the symptoms included in the clusters abdomen, pain and/or eating.
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The addition of CA125 to the SI increased the specificity
and predictive values for the discrimination of malignant
from benign ovarian tumors. This is especially important
in a country where most women with adnexal masses
have their condition detected with ultrasound in primary
health care facilities. Symptom investigation, followed by
CA125 serum level assessment is an affordable and
straightforward approach to the initial triaging of women
at elevated risk of harboring ovarian cancer. This ap-
proach can yield a 63% probability that women referred
to specialized centers (i.e., if one refers women with
positive SI and elevated CA125) indeed have an ovarian
malignancy. On the other hand, 90% of the women with
an adnexal mass, negative SI and negative CA125 levels
will ultimately be found to have a benign ovarian tumor.Table 5 Prevalence of symptoms and tumor markers as relate
Malignant Benign
Stage I Stage II-IV All (n = 116) All
(n = 32) (n = 28) (n = 60) vs.
Cluster % % % %
Abdomen 72 64 68 31 4.7
Pain 44 68 55 22 4.2
Eating 37 54 45 12 6.0
Symptom index (SI) 78 79 78 40 5.5
CA125 47 85 65 24 5.7
HE4 34 86 58 15 7.6
ROMA PI 34 82 57 12 9.5
Symptom index (SI) = presence of at least one of the symptoms included in the clu
Cutoff points in premenopausal women: CA125 = 69.8 U/ml, HE4 = 41.6 pMol/L, ROMA
HE4 = 96.6 pMol/L, ROMA-PI > 18.2%. PPV positive predictive value, NPV negative predOur methodology to evaluate symptom cluster forma-
tion yielded results that closely match Goff et al. recent
results [11]. As they suggested, we can restrict the symp-
tom questionnaire to a shortened version of six ques-
tions encompassing the specific symptoms bloating,
increased abdomen size, feeling full quickly, unable to
eat normally and abdominal/pelvic pain. It is worth
mentioning, however, that diagnostic models are known
to deliver good results in the population at which they
are first developed. But it must be emphasized that, rep-
licating the methodology and using the same instrument
that Goff et al. [9] used in their seminal studies, we
obtained similar performance indicators for isolated
symptoms and symptom clusters. Using the SI, Goff
et al. [11] obtained an overall sensitivity and specificity
of 70% and 86%, respectively, for the discrimination ofd to tumor malignancy and stage
OR (95% CI)
malignant Stage I Stage II-IV Stage II-IV
benign vs. benign vs. benign vs. stage I
(2.4 to 9.4) 5.7 (2.4 to 13.5) 4.0 (1.7 to 9.5) 0.7 (0.2 to 2.1)
(2.1 to 8.2) 2.7 (1.6 to 6.1) 7.3 (2.9 to 18.1) 2.7 (0.9 to 7.8)
(2.8 to 12.7) 4.4 (1.8 to 10.8) 8.4 (3.3 to 21.3) 1.9 (0.7 to 5.4)
(2.7 to 11.3) 5.4 (2.2 to 13.6) 5.6 (2.1 to 14.8) 1.0 (0.3 to 3.5)
(2.8 to 12.2) 3.5 (1.5 to 9.2) 18.4 (5.4 to 79.4) 5.1 (1.3 to 25.1)
(3.7 to 15.6) 2.8 (1.2 to 6.9) 32.7 (10.1 to 105.4) 11.4 (3.2 to 41.4)
(4.4 to 20.3) 3.8 (1.5 to 9.6) 33.5 (11.0 to 102.4) 8.7 (2.6 to 29.5)
sters abdomen, pain and/or eating.
predictive index (PI) = > 5.01%. In postmenopausal women: CA125 = 21.7 U/L,
ictive value.
Table 6 Performance comparison of tumor markers in subsets of women with adnexal tumors (benign or malignant)
with different symptom patterns
Group Marker ROC - AUC ROC-AUC comparison Sensitivity (%) Specificity (%) PPV
(%)
NPV
(%)HE4 vs. CA125 HE4 vs. ROMA CA125 vs. ROMA (95% CI) (95%)
For the differentiation between all malignant tumors from benign tumors (healthy women not included)
All women CA 125 0.81 (0.75 to 0.89) 65.0 (56.3 to 73.7) 75.9 (65.6 to 86.1) 58.2 80.7
HE4 0.74 (0.66 to 0.82) 0.09 0.06 0.37 58.3 (49.4 to 67.3) 84.5 (74.7 to 94.2) 66.0 79.7
ROMA 0.78 (0.71 to 0.86) 56.7 (47.6 to 65.7) 87.9 (78.7 to 97.1) 70.8 79.7
SI Negative CA 125 0.69 (0.52 to 0.86) 46.1 (34.5 to 57.8) 87.1 (70.2 to 100) 40.0 89.7
HE4 0.69 (0.54 to 0.84) 0.98 0.45 0.67 53.1 (42.2 to 65.5) 84.3 (67.5 to 100) 38.9 90.1
ROMA 0.72 (0.57 to 0.87) 38.5 (27.1 to 49.8) 91.4 (74.9 to 100) 45.0 90.7
SI Positive CA 125 0.81 (0.73 to 0.90) 70.2 (57.0 to 83.4) 58.7 (45.3 to 72.1) 63.5 65.8
HE4 0.75 (0.65 to 0.85) 0.27 0.25 0.52 59.6 (45.4 to 73.8) 84.8 (72.9 to 96.7) 80.0 67.2
ROMA 0.78 (0.69 to 0.88) 61.7 (47.6 to 75.7) 82.6 (70.4 to 94.2) 78.4 67.9
For the differentiation between women with Stage I cancer from those with benign tumors
All women CA 125 0.73 (0.63 to 0.83) 46.8 (37.8 to 56.0) 75.9 (63.1 to 88.7) 34.9 83.8
HE4 0.61 (0.50 to 0.71) 0.06 0.09 0.25 34.4 (25.7 to 43.0) 84.5 (71.3 to 97.7) 37.9 82.3
ROMA 0.66 (0.55 to 0.74) 34.4 (25.7 to 43.0) 87.9 (75.2 to 100) 44.0 82.9
SI Negative CA 125 0.52 (0.32 to 0.73) 14.3 (6.1 to 22.5) 87.1 (66.4 to 100) 10.0 91.0
HE4 0.60 (0.39 to 0.81) 0.67 0.90 0.66 28.6 (18.0 to 39.1) 84.3 (69.5 to 100) 15.4 92.2
ROMA 0.61 (0.40 to 0.81) 14.3 (6.1 to 22.5) 91.4 (70.9 to 100) 14.3 91.4
SI Positive CA 125 0.75 (0.63 to 0.86) 56.0 (41.7 to 70.3) 58.7 (41.9 to 75.5) 42.4 71.0
HE4 0.58 (0.44 to 0.74) 0.07 0.20 0.22 36.0 (22.1 to 49.9) 84.8 (67.2 to 100) 56.2 70.9
ROMA 0.65 (0.50 to 0.80) 40.0 (25.8 to 54.2) 82.6 (65.1 to 100) 55.5 71.7
Symptom index (SI) positive = presence of at least one of the symptoms included in the clusters abdomen, pain and/or eating. Cutoff points for each tumor
marker were obtained with ROC analysis. Cutoff points in premenopausal women: CA125 = 69.8 U/ml, HE4 = 41.6 pMol/L, ROMA predictive index (PI) = > 5.01%.
In postmenopausal women: CA125 = 21.7 U/L, HE4 = 96.6 pMol/L, ROMA-PI > 18.2%. PPV positive predictive value, NPV negative predictive value.
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on the other hand, used the SI in women already diag-
nosed with an adnexal mass, and aimed at discriminat-
ing those with a malignancy from the rest. In this
context, we obtained a sensitivity of 78% and a specifi-
city of 60%. In our study, the overall prevalence of can-
cer was 34%, which implies that with a sensitivity of 78%
using the SI as a standalone diagnostic tool, approxi-
mately 50% of the women referred to a specialized cen-
ter will ultimately have cancer. On the other hand, only
15% of the women not referred will have cancer. By
adding CA125 to the strategy, we may improve the posi-
tive predictive value and further reduce the number of
women erroneously referred to a specialized center, even
if we want to refer women with early stage disease (see
Tables 4 and 6).
In the last decade, many studies addressed the symp-
tom experience of women with ovarian cancer, and ovar-
ian cancer can no longer be considered a disease that
does not produce symptoms [9,16,23,24]. Women with
ovarian cancer may experience various symptoms; how-
ever, many of these symptoms have no relationship with
the genital tract. Because these symptoms are unspecific,women and physicians tend to underestimate their im-
portance. Women are often treated for irritable bowel
syndrome, stress, depression or gastritis, months before
they are diagnosed with ovarian cancer [11]. The under-
rating of symptoms by women and doctors may contrib-
ute to ovarian cancer not being timely referred to
specialized centers. In our sample, all women with ma-
lignancies reported some sort of symptom, which is con-
sistent with data from other populations.
The role to be played by HE4 and ROMA and their
significance regarding changes in medical practice are
still under debate [14,25]. Andersen et al. [16] in a pro-
spective study comparing 74 women with ovarian cancer
and 137 healthy women found out that either CA125 or
HE4, when combined with the SI, detected 91.9% of the
cases of malignancy. It is now clear that HE4 is essen-
tially useful to distinguish epithelial ovarian cancer from
other malignant ovarian tumors. Neither stromal nor
germ cell tumors express HE4 and thereby are not dis-
tinguishable from benign tumors by using HE4 [14,25].
We analyzed HE4 and ROMA considering all histologic
types, because our objective was to identify women that
would benefit from a referral to a specialized cancer
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not facilitate the discrimination of malignant from be-
nign ovarian tumors further than CA125 alone.
Our data demonstrated that symptoms may be used
even to differentiate women with early stage ovarian
cancer from those with benign ovarian tumors. In the
present study, 53% of the patients had stage I disease, re-
gardless of the histological type of the tumor, and 78% of
these had positive SI. Rossing et al. [26] demonstrated
that the SI was positive in 62.3% of women with early
stage disease and Goff et al. [27] obtained 57% sensitivity
using the SI. However, in both studies, women were sur-
veyed after diagnosis, whereas in our study we surveyed
the women before surgery and thus before they were in-
formed of the diagnosis of cancer. Because we aimed at
identifying women who would benefit from a referral to
a specialized center, we grouped together women with
epithelial, germ cell and sex cord malignant tumors. On
the other hand, we allocated to a same group women
with borderline epithelial tumors and those with low- or
high-grade invasive epithelial carcinomas. It is well
known that these different histological types display
varying clinical behaviors. Based on a dualistic model of
carcinogenesis, epithelial ovarian carcinoma can be clas-
sified as type I and type II. Type I included low-grade
epithelial carcinomas, generally indolent and easily
detected in stage I. Type II ovarian carcinoma, comprise
high-grade and undifferentiated carcinomas [28]. It has
been well demonstrated that high-grade serous tumors
are rarely diagnosed before they had spread, and for this
type of tumors, diagnostic approaches should be aimed
at diagnosing low-volume tumors, not only tumors at an
early stage [29,30].
Strengths and limitations
The main strengths of this study are that we made
all the interviews and tumor marker collection before
surgery avoiding recall bias. All participants were in-
terviewed in person with a standardized questionnaire.
We also took care to assess symptoms in a relatively
large cohort of healthy women that had attended family
planning and menopause-related medical consultations
at the same center. We found that these women have a
very small likelihood of experiencing symptoms of re-
cent onset and high frequency, which led us to safely
remove these women from symptom performance calcu-
lations. We must also mention that the questionnaire for
the characterization of symptoms was used in Latin
American women for the first time, and the results en-
countered match those from studies addressing women
from different cultural backgrounds [8,10,11].
As a detrimental point, our study suffers from verifica-
tion bias, since we needed the final pathological diagno-
ses for analyses and therefore only women who wereoperated for their adnexal masses had been evaluated.
The performance of symptoms and serum markers was
not evaluated in women who were not operated. An-
other limitation of our study resides in the fact that we
have not analyzed pre and postmenopausal women sep-
arately. Of course, in our analyses, symptoms which ap-
plied only to pre- or postmenopausal women and those
applicable only to sexually active women were not in-
cluded in the multivariate models. Unfortunately, this
approach is not sufficient to rule out this selection bias
because, for example, pelvic pain, which was significantly
associated with malignancy, is frequently reported by
young women with endometrioma [31,32]. As another
weakness of the study, HE4 levels are known to be asso-
ciated with BMI and age, but our analyses did not con-
trol for these variables.
Conclusion
Neither symptoms nor CA125 can be safely used as
standalone instruments to discriminate women with ma-
lignant ovarian tumors from women with benign ad-
nexal masses in lieu of a well performed ultrasound
examination of the pelvis. However, in the foreseeable
future, it is not realistic to expect that such a well
performed ultrasound would be widely available in pri-
mary care facilities, even if we consider that IOTA sim-
ple rules can substantially increase overall ultrasound
performance, at the same time simplifying sonographer
training [5,7]. Collectively, our data indicate that asking
a woman, who already had an adnexal mass incidentally
detected in ultrasound, about the presence, frequency
and onset of six symptoms and determining CA125
levels can facilitate the decision making of primary care
physicians as to whether or not reference the women to
often busy, congested specialized oncology centers.
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